Blood pressure in early autosomal dominant polycystic kidney disease.
暂无分享,去创建一个
Kaleab Z. Abebe | Charity G Moore | K. Bae | C. Moore | A. Chapman | V. Torres | P. Harris | R. Schrier | J. Grantham | M. Hogan | R. Perrone | M. Flessner | F. Rahbari-Oskoui | F. Winklhofer | D. Miskulin | W. Braun | T. Steinman | G. Brosnahan | P. Czarnecki | Kyongtae T Bae | Peter C Harris | Arlene B Chapman | Vicente E Torres | Michael F Flessner | Theodore I Steinman | Jared J Grantham | Robert W Schrier | Dana C Miskulin | Marie C Hogan | Ronald D Perrone | Kaleab Z Abebe | William E Braun | Franz T Winklhofer | Godela Brosnahan | Peter G Czarnecki | Frederic F Rahbari-Oskoui | C. Moore | F. T. Winklhofer
[1] Ann M. Johnson,et al. The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. , 1990, The New England journal of medicine.
[2] G. Beck,et al. Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group. , 1995, Journal of the American Society of Nephrology : JASN.
[3] Y. Tao,et al. Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model. , 2007, American journal of physiology. Renal physiology.
[4] Diego R. Martín,et al. Analysis of baseline parameters in the HALT polycystic kidney disease trials. , 2012, Kidney international.
[5] A. V. Peterson,et al. On the regression analysis of multivariate failure time data , 1981 .
[6] A. Chapman,et al. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. , 2005, Clinical journal of the American Society of Nephrology : CJASN.
[7] S. Yusuf,et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial , 2008, The Lancet.
[8] C. Patch,et al. Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[9] J. Mcateer,et al. Synthesis of renin by tubulocystic epithelium in autosomal-dominant polycystic kidney disease. , 1992, Kidney international.
[10] R. Schrier,et al. Appropriate Blood Pressure Control in type II diabetes (ABCD Trial): implications for complications. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[11] R. Annigeri,et al. Epidemiology, outcomes and validation of RIFLE and AKIN criteria in acute kidney injury (AKI) in critically ill patients: Indian perspective , 2014, Renal failure.
[12] K. Offord,et al. Effect of inhibition of converting enzyme on renal hemodynamics and sodium management in polycystic kidney disease. , 1991, Mayo Clinic proceedings.
[13] Kaleab Z. Abebe,et al. Blood pressure in early autosomal dominant polycystic kidney disease. , 2014, The New England journal of medicine.
[14] S. Colan,et al. Atenolol versus losartan in children and young adults with Marfan's syndrome. , 2014, The New England journal of medicine.
[15] J. Ware,et al. Random-effects models for longitudinal data. , 1982, Biometrics.
[16] M. Woodward,et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. , 2012, JAMA.
[17] K. Bae,et al. MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancement. , 2009, Clinical journal of the American Society of Nephrology : CJASN.
[18] Ann M. Johnson,et al. Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease , 1992, Pediatric Nephrology.
[19] R. Hui,et al. The effect of beta‐blocker therapy on progressive aortic dilatation in children and adolescents with Marfan’s syndrome: a meta‐analysis , 2011, Acta paediatrica.
[20] S. Bangalore,et al. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials , 2013, BMJ.
[21] W. Cushman,et al. Blood Pressure and Mortality in U.S. Veterans With Chronic Kidney Disease , 2013, Annals of Internal Medicine.
[22] C. Wanner,et al. Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. , 2014, Kidney international.
[23] G. Lindop,et al. The anatomy of the renin-secreting cell in adult polycystic kidney disease. , 1988, Kidney international.
[24] S. Strandgaard,et al. Changes in causes of death and risk of cancer in Danish patients with autosomal dominant polycystic kidney disease and end-stage renal disease. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[25] Richard J. Lee,et al. Angiotensin II Activation of Cyclin D1-dependent Kinase Activity* , 1996, The Journal of Biological Chemistry.
[26] R. Schrier. Hypertension and autosomal dominant polycystic kidney disease. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[27] M. Klein,et al. Volume Progression in Polycystic Kidney Disease , 2007 .
[28] Ann M. Johnson,et al. Renal structure and hypertension in autosomal dominant polycystic kidney disease. , 1990, Kidney international.
[29] V. Torres,et al. Effect of sodium chloride, enalapril, and losartan on the development of polycystic kidney disease in Han:SPRD rats. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[30] S. Strandgaard,et al. Improved prognosis in patients with autosomal dominant polycystic kidney disease in Denmark. , 2010, Clinical journal of the American Society of Nephrology : CJASN.
[31] L. M. A. Mahasen. Evolution of the Kidney , 2016 .
[32] W. Thomas,et al. Aldosterone as a renal growth factor , 2010, Steroids.
[33] E. Murphy,et al. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. , 1994, The New England journal of medicine.
[34] J. Miller,et al. The HALT polycystic kidney disease trials: design and implementation. , 2010, Clinical journal of the American Society of Nephrology : CJASN.
[35] Douglas Landsittel,et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. , 2012, Clinical journal of the American Society of Nephrology : CJASN.
[36] T. Mochizuki. 8. Autosomal Dominant Polycystic Kidney Disease , 2013 .
[37] Thomas D. Cook,et al. Introduction to Statistical Methods for Clinical Trials , 2007 .
[38] M. Chonchol,et al. Predictors of autosomal dominant polycystic kidney disease progression. , 2014, Journal of the American Society of Nephrology : JASN.
[39] Ettore Ambrosioni,et al. ESH/ESC guidelines for the management of arterial hypertension: how to implement in daily clinical practice , 2004 .
[40] Nish Chaturvedi,et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. , 2012, The New England journal of medicine.
[41] Geert Molenberghs,et al. Random Effects Models for Longitudinal Data , 2010 .
[42] V. Torres,et al. Autosomal dominant polycystic kidney disease: the last 3 years. , 2009, Kidney international.
[43] Ann M. Johnson,et al. Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. , 2003, Kidney international.
[44] Ann M. Johnson,et al. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. , 2002, Journal of the American Society of Nephrology : JASN.
[45] R. Garrick. Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin–Angiotensin System on Proteinuria in Renal Disease , 2009 .
[46] H. Connolly,et al. Of Marfan's syndrome, mice, and medications. , 2014, The New England journal of medicine.
[47] W. Sweeney,et al. Chronic treatment with lisinopril decreases proliferative and apoptotic pathways in autosomal recessive polycystic kidney disease , 2010, Pediatric Nephrology.
[48] Kaleab Z. Abebe,et al. Angiotensin blockade in late autosomal dominant polycystic kidney disease. , 2014, The New England journal of medicine.
[49] J. Ware,et al. Applied Longitudinal Analysis , 2004 .